Latest News
Hamilton, ON, Canada and Boston, MA, USA. 13 February 2023. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) (“Fusion”), a clinical-stage oncology company focused on developing next-generation targeted alpha therapies (“TATs”) as precision medicines, today announced the acquisition from […]
31 January 2023. Galway, Ireland and Oceanside, California, USA. Palliare, a leading developer of advanced insufflation technologies, has received an expanded 510(k) indication from the U.S. Food and Drug Administration for its EVA15 Insufflator to provide […]
25 January 2023. Dublin, Ireland. Deciphex, a leading provider of pathology software and services, announced today a further €3.9m in funding bringing its full Series B round tally to €15m. The additional investment, led by Seroba […]
14 December, 2022. Cambridge, England. STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced the successful completion […]
23 November 2022, Cambridge, UK. STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces that the first patient has […]
Verona, Italy, 4 October, 2022. Sibylla Biotech today announced the successful close of its €23 million Series A financing round to fund the further development of its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) approach, […]
